Clinical Decision-Making After Receptor Conversion Following Neoadjuvant Therapy in Breast Cancer: A Three-Strategy Framework
Katarzyna Pogoda, Magdalena Czopowicz, Wojciech Olszewski, Monika Durzynska, Piotr Jan Wysocki · 2026
Read Clinical Decision-Making After Receptor Conversion Following Neoadjuvant Therapy in Breast Cancer: A Three-Strategy Framework by Katarzyna Pogoda, Magdalena Czopowicz, Wojciech Olszewski, Monika Durzynska, Piotr Jan Wysocki (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13607326.txt.
Description
Katarzyna Pogoda and four co-authors report, in a 2026 survey, how cancer doctors act when a breast tumor's markers change after drug treatment. Treatment before surgery can flip a tumor's receptor status, which decides which drugs a patient may get next. Guidelines say little about how to adapt, so practice may vary widely.
The team surveyed 104 Polish cancer doctors in late summer 2025. Just over half said they always re-test markers in leftover tumor tissue. Across five change scenarios, doctors most often mixed the old and new marker results when choosing treatment, rather than trusting one alone. Plans driven only by the pre-treatment markers were the least common, at about a quarter of choices.
Catalog record
| CREATOR | Katarzyna Pogoda, Magdalena Czopowicz, Wojciech Olszewski, Monika Durzynska, Piotr Jan Wysocki |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |